The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol

Cancer

Volumn 82, Issue 1, 1998, Pages 159-167

  Silvestrini, Rosella ^a   Daidone, Maria Grazia ^a   Veneroni, Silvia ^a   Benini, Elvira ^a   Scarfone, Giovanna ^a   Zanaboni, Flavia ^b   Villa, Antonella ^a   Presti, Mauro ^c   Danese, Saverio ^d   Bolis, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

^c Ospedale di Voghera   (Italy)

^d Ospedale S Anna   (Italy)

Author keywords

bcl 2; Cell proliferation; Chemotherapy; DNA ploidy; Glutathione S transferase ; Ovarian cancer; P53

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; CYCLOPHOSPHAMIDE; GLUTATHIONE TRANSFERASE; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CANCER STAGING; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CARCINOMA; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TUMOR SUPPRESSOR GENE;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CELL DIVISION; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; FEMALE; FLOW CYTOMETRY; FORECASTING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PLOIDIES; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIOPHARMACEUTICALS; REMISSION INDUCTION; SURVIVAL RATE; THYMIDINE; TREATMENT OUTCOME; TRITIUM; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031894813     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980101)82:1<159::AID-CNCR20>3.0.CO;2-0     Document Type: Article

References (44)

1. Bookman MA, Ozols RF. Factoring outcomes in ovarian cancer. J Clin Oncol 1996; 14:325-7.
2. De Souza PL, Friedlander ML. Prognostic factors in ovarian cancer. Hematol Oncol Clin North Am 1992;6:761-82.
3. Welander CE. The human tumor clonogenic assay used to study ovarian cancers. In: Alberts DS, Surwit EA. Ovarian cancer. Boston: Martinus Nijhoff, 1985:37-52.
4. Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990;82: 582-8.
5. Friedlander ML, Hedley DW, Russel P. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol 1988;6:282-90.
6. Kallionemi OP, Punnonen R, Mattila J, Lehtinen M, Koivula T. Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer. Cancer 1988;61:334-9.
7. Rodenburg CJ, Cornelisse CJ, Heintz PAM, Hermans J, Flueren GJ. Tumor ploidy as a major prognostic factor in advanced ovarian cancer. Cancer 1987;59:317-23.
8. Rice LW, Mark SD, Berkowitz RS, Goff BA, Lage JM. Clinicopathologic variables, operative characteristics, and DNA ploidy in predicting outcome in ovarian epithelial carcinoma. Obstet Gynecol 1995;86:379-85.
9. Erba E, Ubezio P, Vaghi M, Marsoni S, Torri W, Mangioni C, et al. Flow cytometric analysis of DNA content in human ovarian cancers. Br J Cancer 1989;60:45-50.
10. Gajewski WH, Fuller AF Jr., Pastel-Ley C, Flotte TJ, Bell DA. Prognostic significance of DNA content in epithelial ovarian cancer. Gynecol Oncol 1994;53:5-12.
11. Kaern J, Trope CG, Kristensen GB, Tveit KM, Pettersen EO. Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: a prospective study. Am J Obstet Gynecol 1994; 170:479-87.
12. Berek JS, Martinez-Maza O, Hamilton T, Trope C, Kaern J, Baak J, et al. Molecular and biological factors in the pathogenesis of ovarian cancer. Ann Oncol 1993;4:3-16.
13. Khoo SK, Battistutta D, Hurst T, Sanderson B, Ward BG, Free K. The prognostic value of clinical, pathologic, and biologic parameters in ovarian cancer. Cancer 1993;72:531-7.
14. Pfisterer J, Kommoss F, Sauerbrei W, Renz H, du Bois A, Kiechle-Schwarz M, et al. Cellular DNA content and survival in advanced ovarian carcinoma. Cancer 1994;74:2509-15.
15. Erba E, Giordano M, Danova M, Mazzini G, Ubezio P, Torri V, et al. Cell kinetics of human ovarian cancer with in vivo administration of bromodeoxyuridine. Ann Oncol 1994;5: 627-34.
16. Bernabei VM, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR. Flow cytometric evaluation of epithelial ovarian cancer. Am J Obstet Gynecol 1990;162:1584-92.
17. Silvestrini R, Daidone MG, Bolis G, Fontanelli R, Landoni F, Andreola S, et al. Cell kinetics: a prognostic marker in epithelial ovarian cancer. Gynecol Oncol 1989;35:15-9.
18. Silvestrini R, Daidone MG, Valentinis B, Ferraris C, Di Re E, Raspagliesi F, et al. Potentials of cell kinetics in the management of patients with ovarian cancers. Eur J Cancer 1992;28: 386-90.
19. Henriksen R, Strang P, Backstrom T, Wilander E, Tribukait B, Oberg K. Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers. Anticancer Res 1994;14:603-8.
20. Suzuki M, Ohwada M, Tamada T, Tsuru S. Thymidylate synthase activity as a prognostic factor in ovarian cancer. Oncology 1994;51:334-8.
21. Eichhorn JH, Bell DA, Young RH, Swymer CM, Flotte TJ, Preffer RI. DNA content and proliferative activity in ovarian small cell carcinomas of the hypercalcemic type. Implications for diagnosis, prognosis, and histogenesis. Am J Clin Pathol 1992;98:579-86.
22. Scambia G, Benedetti Panici P, Battaglia F, Ferrandina G, Baiocchi G, Greggi S, et al. Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol 1992;10:529-35.
23. Di Leo A, Bajetta E, Biganzoli L, Bohm S, Mariani L, Mènard S, et al. An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. Eur J Cancer 1995;31A:2248-54.
24. Scambia G, Ferrandina G, Marone M, Benedetti Panici P, Giannitelli C, Piantelli M, et al. nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters. J Clin Oncol 1996;14:334-42.
25. van der Zee AGJ, Hollema H, Suurmeijer AJH, Krans M, Sluiter WJ, Willemse PHB, et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13:70-8.
26. Henriksen R, Strang P, Wilander E, Bäckström T, Tribukait B, Öberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki67 expression and flow cytometry. Gynecol Oncol 1994;53:301-6.
27. Henriksen R, Wilander E, Öberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 1995; 72:1324-9.
28. Righetti SC, Della Torre G, Pilotti S, Ménard S, Ottone F, Colnaghi MI, et al. A comparative study of p53 gene mutations, protein accumulation and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689-93.
29. Izquierdo MA, van der Zee AGJ, Vermorken JB, van der Valk P, Beliën JAM, Giaccone G, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995;85:1230-7.
30. Murphy D, McGown AT, Hall A, Cattan A, Crowther D, Fox BW. Glutathione S-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy. Br J Cancer 1992;66:937-42.
31. van der Zee AGJ, van Ommen B, Meijer C, Hollema H, van Bladeren PJ, de Vries EGE. Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. Br J Cancer 1992;66:930-6.
32. Green JA, Robertson LJ, Clark AH. Glutathione S-transferase expression in benign and malignant ovarian tumours. Br J Cancer 1993;68:235-9.
33. Hamada S, Kamada M, Furumoto H, Hirao T, Aono T. Expression of glutathione S-transferase-p in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol 1994;52:313-9.
34. Satoh T, Nishida M, Miyazaki Y, Sugita N, Arisawa Y, Oki A, et al. An immunohistological study on expression of glutathione-S-transferase pi in human ovarian carcinoma. Acta Obstet Gynaecol Japonica 1995;47:931-8.
35. Wrigley EC, McGown AT, Buckley J, Hall A, Crowther D. Glutathione-S-transferase activity and isoenzyme levels measured by two methods in ovarian cancer, and their value as markers of disease outcome. Br J Cancer 1996;73: 763-9.
36. Silvestrini R. Cell kinetics: prognostic and therapeutic implications in human tumours. Cell Prolif 1994;27:579-96.
37. Bolis G, Favalli G, Giardina G, Melpignano M, Pecorelli S, Presti M, et al. A multicenter randomized trial comparing weekly platinum (PW) vs. cyclophosphamide plus platinum (CP) in advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 1994;13:259.
38. Daidone MG, Benini E, Valentinis B, Tomasic G, Bolis G, Villa A, et al. P53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial-stromal tumors. Eur J Cancer 1996; 32A:1388-93.
39. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
40. 3H-dT labeling index in breast cancer. Cell Prolif 1991;24:437-42.
41. Vergote IB, Kaern J, Abeler VM, Pettersen EO, De Vos LN, Trope CG. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 1993;169:40-52.
42. Schueler JA, Cornelisse CJ, Hermans J, Trimbos JB, van der Burg ME, Fleuren GJ. Prognostic factors in well-differentiated early-stage epithelial ovarian cancer. Cancer 1993;71: 787-95.
43. Huettner PC, Weinberg DS, Lage JM. Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features. Am J Pathol 1992;141:699-706.
44. Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW, et al. Guidelines for implementation of clinical DNA cytometry. Cytometry 1993;14:472-7.